--- canonical_name: Bronchogen alternate_names: AEDL, Ala-Glu-Asp-Leu, Alanyl-Glutamyl-Aspartyl-Leucine, ADEL, Ala-Asp-Glu-Leu canonical_topic: Bronchogen for Health & Longevity short_topic_lc: bronchogen creation_date: 2026-0928-1151 creator_ai_fullname: Opus 5.5 ep_keywords: Peptide Bioregulators, Khavinson Peptides, Tetrapeptides --- # Bronchogen for Health & Longevity

Evidence Review created on 09/28/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 5.5 **Also known as:** AEDL, Ala-Glu-Asp-Leu, Alanyl-Glutamyl-Aspartyl-Leucine, ADEL, Ala-Asp-Glu-Leu ## Motivation Bronchogen is a lab-made peptide, a short chain of four amino acids, developed in Russia as a "bioregulator" aimed at the lungs and airways. Its developers propose that it enters airway cells and adjusts which genes are active, helping the airway lining maintain itself. It draws interest from health-focused adults because breathing capacity declines steadily with age and is closely tied to healthy aging. The peptide emerged from a decades-long research program on tissue-specific peptides at a St. Petersburg aging-research institute, which first studied extracts of windpipe lining and later designed this synthetic version. It is sold in Russia as a dietary supplement and, more recently, online as a research peptide, attracting people concerned about smoking-related airway damage, chronic bronchitis, and age-related loss of lung function. This review examines what is known about Bronchogen's possible benefits, its risks, and its practical use, how strong and how independent the underlying evidence is, and how that evidence applies to proactive adults considering it as part of a long-term approach to lung health. **[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)** ## Recommended Reading This section lists the few in-depth, non-vendor sources that discuss Bronchogen or its peptide family directly. - [Peptides: The Science, Uses & Safety – Dr. Abud Bakri](https://www.hubermanlab.com/episode/peptides-the-science-uses-and-safety-abud-bakri) - Andrew Huberman Dr. Abud Bakri discusses the Khavinson peptide family that includes Bronchogen and its shared proposed mechanism, binding DNA (the cell's genetic material) to open or close genes, while noting reliance on Russian studies. - [Peptide Bioregulators: Khavinson Peptides and What the Evidence Shows](https://www.empiremedicaltraining.com/antiaging-regenerative-workshops/resources/peptide-therapy/peptide-bioregulators/) - Empire Medical Training Clinician-education overview, from a company selling peptide-therapy courses, that names Bronchogen within the Khavinson family and weighs their shared proposed mechanism, tissue-specific gene regulation by short peptides, against a single-group, unreplicated evidence base. - [Peptide regulation of gene expression and protein synthesis in bronchial epithelium](https://pubmed.ncbi.nlm.nih.gov/25015171/) - Khavinson et al., 2014 Core laboratory study from the developer's own group (a direct conflict of interest): Bronchogen shifted lung-cell genes and growth proteins in human bronchial cultures and, in cell-free tests, bound DNA. - [Modulating Effect of Peptide Therapy on the Morphofunctional State of Bronchial Epithelium in Rats with Obstructive Lung Pathology](https://pubmed.ncbi.nlm.nih.gov/26468022/) - Kuzubova et al., 2015 Rat study from a separate pulmonology institute: a month of Bronchogen after nitrogen-dioxide exposure modeling COPD (chronic obstructive pulmonary disease, a progressive airflow-limiting lung disease) was followed by airway-lining repair and less inflammation. Only four items qualified: most online Bronchogen content comes from peptide vendors or affiliate marketers, and the remaining papers come from the same developer group already represented. None of the prioritized experts (Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension Magazine, Lifespan.io) has published content on Bronchogen by name; apart from the Huberman Lab episode on the Khavinson peptide family, web searches and on-site searches of their platforms returned no relevant matches. ## Grokipedia [Bronchogen](https://grokipedia.com/page/Bronchogen) AI-generated encyclopedia entry summarizing Bronchogen's sequence, the rat lung-disease studies and the DNA-binding work, and explicitly noting that evidence is confined to preclinical models. ## Examine No Examine article on Bronchogen exists. ## ConsumerLab No ConsumerLab article on Bronchogen exists. ## Systematic Reviews No systematic reviews or meta-analyses for Bronchogen were found on PubMed as of September 28, 2026. No systematic review or meta-analysis covers Bronchogen's clinical benefits or its risks in people; both the claimed effect and the principal risk are unrepresented at this level of evidence. ## Mechanism of Action Bronchogen is the synthetic tetrapeptide Ala-Glu-Asp-Leu (alanine, glutamic acid, aspartic acid, leucine; molecular weight about 446 daltons). Its developers propose that it enters airway cells and their nucleus, binds DNA and histones (proteins that package DNA), and changes which genes are switched on. In human bronchial cell cultures it altered expression of NKX2-1 (a master gene for lung-cell identity), SCGB1A1 (gene for a protective airway secretory protein), FOXA1 and FOXA2 (genes guiding airway-cell development) and raised MUC5AC (a main airway-mucus gene); in cell-free tests it bound DNA at guanine bases ([Khavinson et al., 2014](https://pubmed.ncbi.nlm.nih.gov/25015171/)). Shifts in NKX2-1 and SCGB1A1 tracked changes in promoter methylation (chemical tags that silence genes) ([Ashapkin et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25761685/)). In rats it reduced neutrophilic (first-responder white-blood-cell) airway inflammation ([Kuzubova et al., 2015](https://pubmed.ncbi.nlm.nih.gov/26468022/)). A competing reading: calorimetry (a heat-based binding measurement) found binding that was strong but not specific to any DNA base pair ([Monaselidze et al., 2011](https://pubmed.ncbi.nlm.nih.gov/21240358/)), which sits uneasily with gene-selective action, and all mechanistic work comes from one unreplicated network. - **Half-life:** unmeasured in humans; unmodified tetrapeptides are typically cleaved by blood and gut peptidases (protein-cutting enzymes) within minutes. - **Selectivity and distribution:** lung selectivity is claimed but tissue distribution is untested in living animals or people. - **Metabolism:** breakdown into its four amino acids, with no known CYP450 (liver drug-metabolizing enzyme) involvement; gut uptake through PEPT1 (an intestinal peptide transporter) is proposed only from computer modeling ([Khavinson et al., 2023](https://pubmed.ncbi.nlm.nih.gov/36979488/)). ## Historical Context & Evolution Bronchogen grew out of a research program begun in the 1970s by Vladimir Khavinson at the Military Medical Academy in Leningrad, later continued at the St. Petersburg Institute of Bioregulation and Gerontology. The program first extracted peptide mixtures from calf organs. In the early 1990s an extract of tracheal (windpipe) lining was reported to prolong survival of mice with oxygen-toxicity lung injury, reduce lung-damage markers in rats ([Khavinson et al., 1992](https://pubmed.ncbi.nlm.nih.gov/1480431/)), and lessen scarring in rats with chemically induced lung fibrosis (scarring) ([Khavinson et al., 1994](https://pubmed.ncbi.nlm.nih.gov/7700699/)). The original intended use was treating lung injury and chronic bronchitis. The group then designed a synthetic tetrapeptide modeled on the extract's amino acid composition and patented it in the United States in 2009 for "restoring respiratory organs function" ([US Patent 7625870](https://patents.google.com/patent/US7625870B2/en)). It entered the Russian market as a capsule dietary supplement. Interest for health optimization comes from the developer's aging theory: that tissue-specific peptide signals fade with age and can be replenished. From 2012 the group reported cell-culture effects that were larger in aged cells ([Khavinson et al., 2012](https://pubmed.ncbi.nlm.nih.gov/22808515/)), and a separate pulmonology institute reported rat data in 2015–2017 ([Kuzubova et al., 2015](https://pubmed.ncbi.nlm.nih.gov/26468022/)). Since about 2020, Western longevity communities and research-peptide vendors have promoted it. What has not changed is the absence of randomized human trials and of replication by unaffiliated groups, so its current standing rests on laboratory and animal findings that neither confirm nor exclude a human effect. ## Expected Benefits ### High 🟩 🟩 🟩 No benefit reaches High: no randomized trial in people has been published, and no human clinical outcome has been shown in more than one study. ### Medium 🟩 🟩 No benefit reaches Medium: the only human clinical-outcome data is an unpublished [developer clinical report](https://peptidebio.ru/informaciya/stati/rezultaty-klinicheskih-issledovaniy-bronhogen/) with undisclosed group sizes and no between-group statistical test, which falls short of a single adequately reported trial. ### Low 🟩 #### Fewer Chronic Bronchitis Symptoms as an Add-On A 2007 developer-run study in chronic bronchitis reported less cough, sputum and breathlessness when oral Bronchogen was added to standard care for 20–30 days ([developer clinical report](https://peptidebio.ru/informaciya/stati/rezultaty-klinicheskih-issledovaniy-bronhogen/)). Group sizes and randomization are undisclosed. Rat data point the same way ([Kuzubova et al., 2015](https://pubmed.ncbi.nlm.nih.gov/26468022/)). **Magnitude:** 73% of treated patients reported fewer breathlessness attacks, less cough and less sputum; forced expiratory vital capacity (total air forcefully exhaled after a full breath) rose from about 2,850 mL to 3,800 mL with Bronchogen versus 3,200 mL with standard care alone, an unusually large gain never independently reproduced. ### Speculative 🟨 #### Airway Lining Repair and Less Lung Inflammation In rats with nitrogen-dioxide lung injury, a month of Bronchogen restored ciliated (mucus-clearing) cells and raised secretory IgA (the airway's frontline antibody) ([Kuzubova et al., 2015](https://pubmed.ncbi.nlm.nih.gov/26468022/)). Basis: animal data only. #### Protection Against Lung Scarring and Acute Lung Injury The developer's patent reports that low-dose injections lessened chemically induced lung scarring, oxygen-toxicity damage and bacterial lung inflammation in rats ([US Patent 7625870](https://patents.google.com/patent/US7625870B2/en)). Basis: unreplicated animal experiments only. #### Slowing Age-Related Decline in Airway Cell Renewal Bronchogen raised cell-maturation markers more in aged than young human bronchial cultures ([Khavinson et al., 2012](https://pubmed.ncbi.nlm.nih.gov/22808515/)) and stimulated lung tissue samples from old rats ([Zakutskiĭ et al., 2006](https://pubmed.ncbi.nlm.nih.gov/17152728/)). Basis: laboratory data only. #### Longer Healthy Lifespan No lifespan study of Bronchogen exists. The longevity claim is extrapolated from other Khavinson peptides, whose mouse studies reported slower aging markers ([Anisimov et al., 2001](https://pubmed.ncbi.nlm.nih.gov/11163623/)). Basis: indirect animal data only. #### Support During Viral Lung Infections A developer-group review proposes Bronchogen as an airway-protecting add-on in COVID-19 (coronavirus disease 2019) because it promotes bronchial cell renewal ([Khavinson et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32987757/)). No infection study has tested it. Basis: hypothesis only. ## Benefit-Modifying Factors - **Genetic polymorphisms:** No gene variant has been studied for response. Because the proposed action runs through promoter methylation, inherited or smoking-related methylation differences could alter response. Lung damage from SERPINA1 variants (gene for a lung-protecting enzyme blocker) has no known peptide remedy. - **Baseline lung function and inflammation:** The only reported human signal comes from people with chronic bronchitis. Adults with normal spirometry (a breathing test measuring airflow) and no cough or sputum have no measured target, so a detectable benefit is unlikely. - **Sex:** No sex-specific data exist; the [developer clinical report](https://peptidebio.ru/informaciya/stati/rezultaty-klinicheskih-issledovaniy-bronhogen/) did not break results down by sex, and the animal studies did not report sex differences. - **Pre-existing conditions:** Chronic bronchitis and smoking-type airway injury are the only conditions with any human or animal data; asthma, lung fibrosis and post-infection recovery have no human data. - **Age:** Cell-culture effects were larger in aged cells, which is why older adults are the intended users; no human data compare age groups, and older adults more often carry undiagnosed lung disease needing standard evaluation. ## Potential Risks & Side Effects ### High 🟥 🟥 🟥 No risk reaches High: no adverse event has been documented in more than one human study, because only one developer-run human report of undisclosed size exists. ### Medium 🟥 🟥 No risk reaches Medium: no human trial or consistent observational data record adverse events for Bronchogen, and the single [developer clinical report](https://peptidebio.ru/informaciya/stati/rezultaty-klinicheskih-issledovaniy-bronhogen/) states none occurred. ### Low 🟥 ### Speculative 🟨 #### Theoretical Promotion of Abnormal Cell Growth Bronchogen raised Ki67 (a marker of dividing cells) and Mcl-1 (a cell-death-blocking protein that lung cancers exploit) in bronchial cell cultures ([Khavinson et al., 2014](https://pubmed.ncbi.nlm.nih.gov/25015171/)). Basis: laboratory data only; no tumor study exists. #### Contaminated, Mislabeled or Non-Sterile Products Research-grade injectable vials are sold without drug-grade sterility or identity testing, and one developer-line capsule listing names arginine instead of leucine ([product listing](https://peptide-products.com/en/online-store/cytogens-peptide-bio/bronchogen-detail)). Basis: product-quality reasoning; no harm reports. #### Delayed Care for Progressive Lung Disease Self-treating cough or breathlessness with an untested peptide can postpone diagnosis of COPD, asthma or lung cancer. Basis: reasoning from marketing claims of lung repair; no documented cases. #### Digestive Upset and Allergic Reactions A promotional source mentions rare mild digestive upset ([Jay Campbell article](https://jaycampbell.com/bioregulators/bronchogen-peptide/)); injected peptides can cause allergic or injection-site reactions. Basis: isolated anecdotal reports only. ## Risk-Modifying Factors - **Genetic polymorphisms:** No variant affecting Bronchogen handling is known; peptidases rather than CYP450 enzymes break it down, so standard drug-metabolism gene tests do not apply. - **Baseline biomarkers:** Abnormal spirometry, resting oxygen saturation below 94%, or a lung nodule on imaging signal disease that needs standard evaluation, raising the cost of any delay. - **Sex:** No sex differences are documented; safety in pregnancy and breastfeeding is untested, and the developer lists both as contraindications. - **Pre-existing conditions:** Active or past cancer and heavy smoking raise the stakes of the theoretical growth signal; weakened immunity raises infection risk from non-sterile injections; lactose intolerance matters for lactose-containing capsules. - **Age:** Older adults carry higher background rates of undiagnosed lung cancer and COPD, magnifying the cost of delayed evaluation; no age-specific safety data exist. ## Key Interactions & Contraindications - **Prescription inhaled therapies (tiotropium, salmeterol, budesonide):** Monitor. No pharmacological interaction is known, and the [developer clinical report](https://peptidebio.ru/informaciya/stati/rezultaty-klinicheskih-issledovaniy-bronhogen/) added Bronchogen to such therapy. The clinical consequence to avoid is loss of control if inhalers are stopped. Mitigation: prescribed inhalers continue unchanged. - **Prescription cancer therapies (osimertinib, pembrolizumab, platinum chemotherapy, meaning platinum-based cell-killing drugs):** Caution. The theoretical cell-growth signal could oppose anticancer intent, a consequence never studied. Mitigation: use is deferred during active cancer treatment unless the treating oncologist has reviewed it. - **Prescription immunosuppressants (immune-dampening drugs: prednisone, methotrexate, tacrolimus):** Caution with injectable products. Consequence: higher risk of injection-site or bloodstream infection from non-sterile vials. Mitigation: oral capsules, or injectables with documented sterility and endotoxin (bacterial toxin) testing. - **Over-the-counter cough and mucus medicines (guaifenesin, dextromethorphan):** Monitor. No interaction is known; the consequence is masked symptoms that delay evaluation. Mitigation: persistent cough beyond 8 weeks prompts medical assessment regardless of peptide use. - **Other Khavinson peptide supplements (Chonluten, Taxorest, Thymalin):** Monitor. Frequently combined for additive airway or immune effects, which are theoretical; the consequence is untested combined exposure and unattributable reactions. Mitigation: one new peptide introduced at a time, at least 2 weeks apart. - **Supplements with additive airway effects (N-acetylcysteine 600–1,200 mg/day):** Monitor. N-acetylcysteine thins mucus and may reduce COPD flare-ups; combined use may add effects on mucus, with no known harm. Mitigation: separate start dates to judge each agent. - **Smoking and vaping:** Caution, counteracting effect. Continued smoke exposure drives the airway injury Bronchogen targeted in rats, likely overwhelming any peptide effect. Mitigation: smoking cessation before or alongside any course. **Populations who should avoid Bronchogen:** - Pregnant or breastfeeding women (developer contraindication; no safety data) - Anyone under 18 years of age - Active cancer, or a lung nodule under evaluation (Lung-RADS category 3–4 on low-dose CT, a radiology scoring system for suspicious nodules on computed tomography scans) - Acute breathing problems: resting oxygen saturation below 92% or breathlessness at rest, which need urgent care - Known hypersensitivity to the peptide or capsule ingredients, including lactose - Severe immunosuppression (absolute neutrophil count below 1,000 cells/µL) for injectable products ## Risk Mitigation Strategies - **Medical evaluation before starting:** Spirometry for anyone with cough or breathlessness, and annual low-dose CT for smokers aged 50–80 with 20 pack-years (packs per day × years smoked), prevents delayed diagnosis of disease Bronchogen does not treat. - **Prescribed therapy kept unchanged:** Inhalers and other prescribed lung treatments continue at their current doses, preventing loss of disease control from substitution. - **Oral developer-line capsules over research vials:** Choosing capsules avoids injection-site reactions and infection risk from non-sterile, unregulated injectable products. - **Identity and purity verification:** A batch certificate showing purity of at least 98% and mass spectrometry (a molecular-weight test) matching 446 daltons, plus endotoxin testing for injectables, reduces mislabeling and contamination risk. - **Time-limited courses:** Courses of 20–30 days, repeated no more than every 3–6 months, limit cumulative exposure to the theoretical cell-growth signal. - **Cancer-history screen:** Avoiding use with active cancer or cancer treated within the past 5 years mitigates the theoretical growth-promoting risk. - **Stop-and-evaluate triggers:** Coughing blood, unexplained weight loss over 5% in 6 months, fever, or oxygen saturation below 94% end the course and prompt evaluation, preventing delayed diagnosis. - **Single-agent introduction:** Starting Bronchogen alone for at least 2 weeks before adding other peptides allows any adverse reaction to be attributed correctly. ## Therapeutic Protocol - **Developer oral course:** 2 capsules (0.275 g each) twice daily with food for 30 days, repeated after 3–6 months, per the St. Petersburg Institute of Bioregulation and Gerontology's Peptide Bio line ([product listing](https://peptide-products.com/en/online-store/cytogens-peptide-bio/bronchogen-detail)). - **Developer clinical-report regimen:** 1–2 capsules twice daily for 20–30 days, added to standard chronic bronchitis treatment in the 2007 [developer clinical report](https://peptidebio.ru/informaciya/stati/rezultaty-klinicheskih-issledovaniy-bronhogen/). - **Injectable research-peptide approach:** 500–1,000 µg daily by subcutaneous (under-the-skin) injection for 40 days, or 6 days on and 1 off for 7 weeks, popularized by Jay Campbell, who earns vendor affiliate commissions ([Jay Campbell article](https://jaycampbell.com/bioregulators/bronchogen-peptide/)). - **Conventional lung-health approach:** Pulmonologists emphasize smoking cessation, vaccination, aerobic training and, for diagnosed disease, inhaled therapy and pulmonary rehabilitation (supervised exercise and education); this track is pursued with or without peptide courses. - **Dose context from animal data:** Rat studies in the developer's patent used 0.2 µg/kg ([US Patent 7625870](https://patents.google.com/patent/US7625870B2/en)), about 2 µg for a 70 kg adult by body-surface-area scaling, far below capsule and injectable protocols. No human dose-finding study exists. - **Time of day:** Developer protocols take capsules with morning and evening meals; the injectable protocol uses evening dosing about 2 hours after the last meal. No study compares timing. - **Half-life:** Not measured in humans; unmodified tetrapeptides usually persist only minutes in blood, so any lasting effect would depend on the proposed gene-expression changes rather than sustained blood levels. - **Single vs split dosing:** Oral protocols split the daily amount into two doses with meals; injectable protocols use a single daily dose. Neither schedule has been compared. - **Genetic polymorphisms:** No pharmacogenetic variant is known to change dosing; breakdown by peptidases bypasses common CYP450 variants. - **Sex:** Protocols are identical for men and women; no sex-specific dosing data exist. - **Age:** The developer positions courses for middle-aged and older adults; no age-based dose adjustment has been studied, and baseline spirometry precedes use in older adults. - **Baseline biomarkers:** Protocols are not titrated to any biomarker; baseline spirometry and oxygen saturation document starting status and allow later comparison. - **Pre-existing conditions:** The only reported human use is as an add-on in chronic bronchitis; in COPD or asthma, courses are layered onto prescribed inhalers, not substituted for them. ## Discontinuation & Cycling - **Short-term, not lifelong:** All described protocols are time-limited courses, 20–30 days oral or 6–7 weeks injectable, rather than continuous daily use. - **Withdrawal effects:** None reported; no dependence, rebound breathlessness or rebound cough has been described after stopping. - **Tapering:** Not required; every described protocol ends abruptly at course completion. - **Cycling:** The developer repeats courses every 3–6 months and the influencer oral protocol uses 4–6 month breaks; whether cycling preserves responsiveness has never been tested. - **Stopping early:** Courses end at new warning symptoms, such as coughing blood, fever or worsening breathlessness, which call for medical evaluation. ## Sourcing and Quality - **Developer-line capsules:** Peptide Bio (TD Peptid Bio) produces Bronchogen capsules (60 × 0.275 g) linked to the St. Petersburg Institute of Bioregulation and Gerontology, sold as a Russian dietary supplement; peptide content per capsule is not disclosed. - **Label inconsistency:** One English-language listing names alanine, aspartic acid, glutamic acid and arginine, not leucine, and publications alternate between Ala-Glu-Asp-Leu and Ala-Asp-Glu-Leu, so identity cannot be assumed from the label. - **Research-grade vials:** Online vendors sell 20 mg lyophilized (freeze-dried) vials labeled "not for human consumption", made without drug-grade manufacturing oversight; purity claims rest on vendor-supplied certificates. - **What to look for:** A batch-specific third-party certificate of analysis with high-performance liquid chromatography (a purity test) showing at least 98%, mass spectrometry matching 446.45 daltons, and sterility and endotoxin testing for injectables. - **Compounding pharmacies:** Bronchogen is neither approved by the US Food and Drug Administration (FDA) nor an eligible bulk substance, so US compounding pharmacies do not legally prepare it. ## Practical Considerations - **Time to effect:** The [developer clinical report](https://peptidebio.ru/informaciya/stati/rezultaty-klinicheskih-issledovaniy-bronhogen/) describes symptom changes within a 20–30 day course, and rat studies assessed effects after one month ([Kuzubova et al., 2015](https://pubmed.ncbi.nlm.nih.gov/26468022/)). Confirming any lung-function change would require repeat spirometry over months. - **Common pitfalls:** Treating new cough or breathlessness with a peptide instead of seeking evaluation; assuming vials and capsules are equivalent; combining several peptides at once, which makes effects unattributable; and trusting vendor summaries that present rat data as human results. - **Regulatory status:** Not approved as a drug anywhere; sold in Russia as a dietary supplement and elsewhere as a research chemical. The FDA has not evaluated it, and its US patent has lapsed. - **Cost and funding incentives:** A 30-day developer course needs two 60-capsule packs, roughly €140. With no active patent holder and no insurer coverage, no party has a financial incentive to fund large trials, a structural reason the evidence remains thin. ## Interaction with Foundational Habits - **Sleep:** None known. No study has measured sleep effects, and no sleep disruption is reported. Indirectly, less nighttime cough would aid sleep if the unconfirmed symptom benefit is real. Evening injection timing in the influencer protocol has no sleep-based rationale. - **Nutrition:** Indirect. Developer protocols take capsules with meals, although digestive peptidases likely break down much of the peptide; no nutrient depletion is known. Capsules contain lactose, and diets rich in fruit, vegetables and fish are independently linked to better lung function. - **Exercise:** None studied; potentially potentiating indirectly. Aerobic training and pulmonary rehabilitation improve breathlessness and exercise capacity on their own; no data show Bronchogen changes training response or needs timing around workouts. - **Stress management:** None known. No effect on cortisol or the stress response has been measured. Breathing techniques such as pursed-lip breathing (slow exhaling through pursed lips) ease breathlessness-related anxiety independently of any peptide. ## Monitoring Protocol & Defining Success Baseline testing before a first course documents lung status and screens out disease needing standard care: spirometry with FEV1 (forced expiratory volume in one second) and FVC (forced vital capacity, total air exhaled), resting oxygen saturation, a blood count, and kidney and liver panels, which together provide a reference point for later comparison. Current or former heavy smokers aged 50–80 also qualify for low-dose chest CT screening. Ongoing monitoring follows the course schedule: symptom review at 2 and 4 weeks, repeat spirometry and oxygen saturation at the end of each 30-day course, then every 6–12 months while courses continue, with blood tests yearly or after any injectable course. | Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes | |-----------|--------------------------|-----------------|---------------| | FEV1/FVC ratio | ≥ 0.75 | Detects airflow obstruction | Conventional cutoff: below 0.70 or below the lower limit of normal signals obstruction; test after a bronchodilator (airway-opening inhaler) preferred; no fasting | | FEV1 (% predicted) | ≥ 90% of predicted | Tracks lung-function change | Conventional normal ≥ 80%; compare with own baseline; test at the same time of day | | SpO2 at rest | 96–99% | Screens gas exchange | SpO2 = oxygen saturation by pulse oximetry; conventional acceptable ≥ 94%; warm fingers, no nail polish | | hs-CRP | < 1.0 mg/L | General inflammation marker | hs-CRP = high-sensitivity C-reactive protein; conventional < 3.0 mg/L; repeat if recent infection; no fasting needed | | Blood eosinophils | 100–300 cells/µL | Flags allergic-type airway inflammation | Part of the CBC (complete blood count); conventional upper limit about 500 cells/µL; morning draw preferred due to daily variation | | ALT | < 25 U/L | Liver safety baseline | ALT = alanine aminotransferase, a liver enzyme; conventional upper limit 40–55 U/L; pair with AST (aspartate aminotransferase) | | eGFR | > 90 mL/min/1.73 m² | Kidney function baseline | eGFR = estimated glomerular filtration rate; conventional ≥ 60; pair with creatinine and cystatin C; avoid heavy exercise 24 h before | Qualitative markers of success: - Daily cough and sputum frequency - Breathlessness on stairs or exertion (0–4 breathlessness scale) - Chest infections or flare-ups per year - Exercise tolerance, such as a timed walk - Sleep disruption from nighttime cough ## Emerging Research - **No registered human trials:** A ClinicalTrials.gov search on September 28, 2026 found no registered trial of Bronchogen or AEDL, so no NCT ID exists. A randomized, placebo-controlled trial with spirometry and flare-up endpoints could strengthen or weaken the case decisively. - **Cell-entry route:** Computer docking suggests AEDL fits binding sites of PEPT1 and LAT1 (an amino acid transporter), a possible route into cells ([Khavinson et al., 2023](https://pubmed.ncbi.nlm.nih.gov/36979488/)). Measured uptake in human cells or blood would strengthen the oral-use case; failure to detect it would weaken it. - **Epigenetic mechanism:** Promoter-methylation findings for NKX2-1 and SCGB1A1 in aging bronchial cultures ([Ashapkin et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25761685/)) await confirmation in human airway samples, which would test whether the proposed mechanism operates in people. - **DNA-binding specificity:** Calorimetry showed binding without base-pair preference ([Monaselidze et al., 2011](https://pubmed.ncbi.nlm.nih.gov/21240358/)), while fluorescence work reported a preference for CTG-containing sequences (a specific three-letter DNA pattern) ([Fedoreyeva et al., 2011](https://pubmed.ncbi.nlm.nih.gov/22117547/)); resolving this determines whether tissue-specific gene targeting is plausible. - **Infection-recovery hypothesis:** The developer group proposes airway-protecting peptides, including AEDL, as add-ons in COVID-19 ([Khavinson et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32987757/)); no patient data exist, and a negative infection study would weaken this claim. - **Activity in other organisms:** A plant-biology group, publishing without the developer as co-author, reports AEDL activates metabolism and autophagy (cellular self-cleaning) in tobacco root cells ([Lazareva et al., 2025](https://pubmed.ncbi.nlm.nih.gov/41303518/)), confirming the molecule is biologically active but offering no evidence of human lung benefit. ## Conclusion Bronchogen is a short, lab-made chain of four amino acids promoted as a lung-specific "bioregulator" for people who want to keep their airways resilient with age. Its appeal is easy to see: a short oral or injectable course said to renew the airway lining and calm long-running inflammation. The evidence behind those claims is thin. Most of it comes from cell cultures and rat experiments, and nearly all of it originates with the research institute that developed and sells the product, a conflict of interest that runs through the whole literature. Much of the online commentary comes from peptide sellers, paid promoters and companies selling peptide training. The only human data come from one unpublished developer report that omits basic study details. The proposed way it works, switching lung-maintenance genes back on, is intriguing but unconfirmed in people, and whether the peptide survives digestion is unknown. On the risk side, no harms have been documented, but that reflects a lack of study rather than demonstrated safety. The practical concerns are product identity and cleanliness, especially for research-grade injectable vials; a theoretical growth-promoting signal that matters most for people with a cancer history; and the chance of delaying proper evaluation of cough or breathlessness. Overall, Bronchogen sits at the speculative end of the longevity toolkit: plausible to its developers, low in documented risk, and largely untested in humans. **[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**